GlassScriptPhysician profile
David A Miller
NPI 1487793089
$1,535.75
in general payments reported to CMS, 2019-2025
23 companies · $214 in 2025
The $214 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $447 · 2020: $236 · 2021: $270 · 2022: $213 · 2023: $59.92 · 2024: $96.29 · 2025: $214.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $286 · Long Term Medical Supply Or Device Loan: $84.47.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $285.53 |
| Long Term Medical Supply Or Device Loan | $84.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $341.80 | 2019-2023 | Rotarix, Bexsero |
| Gilead Sciences, INC. | $255.72 | 2019-2025 | |
| Abbvie INC. | $174.68 | 2019-2022 | |
| Lilly USA, LLC | $100.25 | 2019-2025 | Mounjaro |
| Ironshore Pharmaceuticals INC. | $94.05 | 2019 | |
| Amgen INC. | $90.94 | 2019-2021 | |
| Baxter Healthcare | $84.47 | 2025 | Hillrom - Oae Hearing Screener |
| Novo Nordisk INC | $43.23 | 2021-2023 | Ozempic, Rybelsus |
| Merck Sharp & Dohme LLC | $38.83 | 2019-2022 | |
| Verity Pharmaceuticals INC. | $34.69 | 2024 | Tlando |
| Boehringer Ingelheim Pharmaceuticals, INC. | $31.33 | 2021 | |
| Sanofi Pasteur INC. | $29.71 | 2019-2021 | |
| Alkermes, INC. | $29.17 | 2025 | Vivitrol |
| Pfizer INC. | $27.33 | 2019-2025 | |
| Otsuka America Pharmaceutical, INC. | $26.88 | 2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $22.01 | 2024 | Intellis Adaptivestim |
| Hologic Sales and Service, LLC | $21.38 | 2024 | Thinprep 2000 Processor, Third Wave, Aptima |
| Abbott Laboratories | $19.11 | 2023 | Proclaim |
| Neurocrine Biosciences, INC. | $16.66 | 2021 | |
| Genentech USA, INC. | $14.67 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.62 | 2020 | |
| Dynavax Technologies Corporation | $13.19 | 2019 | |
| Global Blood Therapeutics, INC. | $12.03 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Miller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.